Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPERA I: Ocrelizumab vs Interferon Beta-1a in Relapsing MS
NCT01247324Phase 3Completed
- Sponsor
- Roche
- Start
- Aug 2011
- Primary completion
- Apr 2015
- Modality
- Monoclonal Antibodies
- Countries
- 32
01
Overview
Phase 3, randomised, double-blind trial of ocrelizumab in multiple sclerosis (MS) (2 arms), sponsored by Roche. Primary endpoint: Annualized Relapse Rate at 96 weeks. Started Aug 2011; status: completed.
02
Drugs
ocrelizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT01247324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01247324.